New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2014
08:36 EDTPCYCPharmacyclics price target raised to $163 from $132 at RW Baird
Baird raised its price target on Pharmacyclics following CLL label expansion of Imbruvica as well as positive prescription trends. The firm believes its approval gives a head start on competitors as well as aiding in reimbursement efforts. Shares are Outperform rated.
News For PCYC From The Last 14 Days
Check below for free stories on PCYC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
14:32 EDTPCYCPharmacyclics estimates raised ahead of Q2 report at Goldman
Goldman raised Pharmacyclics' Q2 Imbruvica US sales estimate to $93M from $82M, vs. consensus of $88M and 2014 to $409M from $383M based on IMS data. The firm rates shares a Buy with a $162 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use